SCHEDULE Filed 2025-01-31 Event 2025-01-31 SEC 0000905148-25-000308 →

VIKING GLOBAL INVESTORS LP → BridgeBio Pharma, Inc. BBIO

Stake: 11.70% Shares: 22,055,375 CUSIP: 10806X102 Class: Common Stock, par value $0.001 per share

Item 4 — Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On January 31, 2025, VGEM, VLFM and Opportunities Fund sold 143,266 shares of Common Stock, 57,020 shares of Common Stock and 2,865,330 shares of Common Stock, respectively, at a price of $34.90 per share.

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

10 13D/G filings on this issuer

9 other filings besides this one

Filer Track Record

22 filings by this filer

21 other filings in the data moat

Short Interest · settle 2026-07-15

DTC 5.38

25,750,649 shares short · +6.8% vs prior

Institutional Consensus · 2026-03-31

Held by elite portfolio managers

2 holders · $880.00M

Point72 Asset MgmtViking Global

Post-Filing Returns · since 2025-01-31 on BBIO

+1 day

-9.3%

+5 days

-2.0%

+30 days

-3.5%

+60 days

-3.5%

+90 days

+12.2%

+180 days

+33.4%

Anchor price 34.21 on closest trading day on/after 2025-01-31. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Other 13D/G Filings on BridgeBio Pharma, Inc.

Filed	Form	Filer	Stake	Shares
2026-07-10	SCHEDULE 13D/A	VIKING GLOBAL INVESTORS LP	5.00%	9,792,219	view →
2026-05-29	SCHEDULE 13G	Farallon Capital Partners, L.P.	—	—	view →
2026-04-02	SCHEDULE 13D/A	VIKING GLOBAL INVESTORS LP	6.10%	11,842,434	view →
2025-07-01	SCHEDULE	VIKING GLOBAL INVESTORS LP	9.80%	18,602,920	view →
2025-05-14	SCHEDULE	KKR Genetic Disorder L.P.	7.00%	13,260,971	view →
2025-03-07	SCHEDULE	KKR Genetic Disorder L.P.	10.10%	19,260,971	view →
2023-07-20	SC	VIKING GLOBAL INVESTORS LP	—	—	view →
2021-01-26	SC	Eidos Therapeutics, Inc.	—	—	view →
2020-06-01	SC	KKR Genetic Disorder L.P.	—	—	view →

Other Filings by VIKING GLOBAL INVESTORS LP

Filed	Form	Issuer	Stake	Shares
2026-07-10	SCHEDULE 13D/A	BridgeBio Pharma, Inc. BBIO	5.00%	9,792,219	view →
2026-06-12	SCHEDULE 13D	STANDARD BIOTOOLS INC. LAB	15.00%	58,651,170	view →
2026-05-18	SCHEDULE 13G	Artiva Biotherapeutics, Inc. ARTV	—	—	view →
2026-04-02	SCHEDULE 13D/A	BridgeBio Pharma, Inc. BBIO	6.10%	11,842,434	view →
2025-07-01	SCHEDULE	BridgeBio Pharma, Inc. BBIO	9.80%	18,602,920	view →
2023-11-07	SC	Cazoo Group Ltd	—	—	view →
2023-09-22	SC	Cazoo Group Ltd	—	—	view →
2023-07-20	SC	BridgeBio Pharma, Inc. BBIO	—	—	view →
2023-04-27	SC	Cazoo Group Ltd	—	—	view →
2023-02-27	SC	Cazoo Group Ltd	—	—	view →
2022-03-04	SC	Ginkgo Bioworks Holdings, Inc. DNABW	—	—	view →
2021-10-01	SC	Ginkgo Bioworks Holdings, Inc. DNABW	—	—	view →
2019-07-12	SC	Arbutus Biopharma Corp ABUS	—	—	view →
2019-07-12	SC	Urovant Sciences Ltd.	—	—	view →
2019-07-12	SC	Axovant Gene Therapies Ltd.	—	—	view →
2019-07-12	SC	Myovant Sciences Ltd.	—	—	view →
2019-03-19	SC	Axovant Sciences Ltd.	—	—	view →
2019-01-03	SC	Axovant Sciences Ltd.	—	—	view →
2019-01-03	SC	Urovant Sciences Ltd.	—	—	view →
2019-01-03	SC	Arbutus Biopharma Corp ABUS	—	—	view →

Showing 20 of 21

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →